Aug
It wasn’t long ago that many in the medical community gave those living with HIV/AIDS a bleak prognosis. But today, while we’ve yet to cure this disease, more and more people with HIV are living longer and fuller lives. However, treatment can have specific side effects, such as facial lipoatrophy. For those searching for liquid facelift treatment in Washington DC, Dr. Cheryl Burgess, Medical Director at the Center for Dermatology and Dermatologic Surgery, a board-certified dermatologist, offers a Sculptra treatment designed to combat the effects of facial lipoatrophy.
Facial lipoatrophy is a side-effect caused by Highly Active Anti-Retroviral Therapy (HAART). This condition causes fat loss along with the redistribution of fat in the face. Studies show that the majority of HAART patients develop facial lipoatrophy within a year following treatment.
Patients with this facial lipoatrophy have reported increased depression and anxiety. Unfortunately, some patients decide not to continue their HAART treatment to avoid facial lipoatrophy (also known as facial wasting) due to these psychological strains.
Another troubling development has been the dissolution of privacy, so crucial to HIV patients. Many have had to disclose their condition to employers due to the visible impact of facial lipoatrophy.
FDA-approved Sculptra works as a safe bio-compatible bio-stimulate that makes your skin remodel and produce more collagen. This injectable treatment helps restore your face’s lost volume and reduces conditions such as:
Sculptra is typically injected into the facial tissue (along with a topical anesthetic if needed). Results usually start to show after one month and may last up to two years!
You don’t have to live with facial lipoatrophy any longer. Allow Dr. Burgess and her trusted team to reclaim your natural face with Sculptra. Don’t delay. Make your appointment to see Dr. Cheryl Burgess at the Center for Dermatology and Dermatologic Surgery today! Give us a call at (202) 955-5757 and pay us a visit at 2311 M St. NW, Suite. 504, Washington, DC, 20037.